Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-16

Clinical Trial Update: A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial of NewGam, a human immunoglobulin 10%, in primary immunodeficiency diseases has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NewGam (intravenous immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Primary Immunodeficiency Diseases | Phase 3 | Status: COMPLETED | Results posted: 2017-03-16